Progyny, Inc. (NASDAQ:PGNY) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC decreased its holdings in Progyny, Inc. (NASDAQ:PGNY) by 38.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,717 shares of the company’s stock after selling 3,554 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Progyny were worth $213,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Gotham Asset Management LLC purchased a new position in shares of Progyny during the 3rd quarter valued at approximately $1,116,000. International Assets Investment Management LLC lifted its holdings in Progyny by 9,381.3% during the fourth quarter. International Assets Investment Management LLC now owns 158,053 shares of the company’s stock valued at $5,876,411,000 after purchasing an additional 156,386 shares in the last quarter. Invesco Ltd. grew its position in shares of Progyny by 67.0% in the third quarter. Invesco Ltd. now owns 888,427 shares of the company’s stock valued at $30,224,000 after purchasing an additional 356,529 shares during the period. Northern Trust Corp increased its stake in shares of Progyny by 1.3% during the third quarter. Northern Trust Corp now owns 1,166,806 shares of the company’s stock worth $39,695,000 after purchasing an additional 15,208 shares in the last quarter. Finally, Deutsche Bank AG raised its position in shares of Progyny by 12.7% during the 3rd quarter. Deutsche Bank AG now owns 42,029 shares of the company’s stock worth $1,430,000 after purchasing an additional 4,738 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Trading Down 1.4 %

Shares of PGNY opened at $32.04 on Friday. The company’s 50-day moving average price is $35.84 and its 200 day moving average price is $35.62. Progyny, Inc. has a 12-month low of $29.44 and a 12-month high of $44.95. The firm has a market cap of $3.08 billion, a P/E ratio of 51.68, a price-to-earnings-growth ratio of 1.34 and a beta of 1.48.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.04. The business had revenue of $269.94 million for the quarter, compared to the consensus estimate of $274.08 million. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The business’s revenue was up 26.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.03 EPS. Equities research analysts forecast that Progyny, Inc. will post 0.7 earnings per share for the current year.

Insider Activity at Progyny

In related news, Chairman David J. Schlanger sold 71,272 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $37.80, for a total transaction of $2,694,081.60. Following the completion of the transaction, the chairman now directly owns 86,312 shares in the company, valued at approximately $3,262,593.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Chairman David J. Schlanger sold 20,000 shares of the business’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $38.50, for a total transaction of $770,000.00. Following the completion of the transaction, the chairman now directly owns 86,312 shares of the company’s stock, valued at approximately $3,323,012. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman David J. Schlanger sold 71,272 shares of the company’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $37.80, for a total value of $2,694,081.60. Following the sale, the chairman now owns 86,312 shares in the company, valued at approximately $3,262,593.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 120,515 shares of company stock worth $4,570,131. 12.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms recently issued reports on PGNY. SVB Leerink initiated coverage on Progyny in a report on Monday, February 26th. They issued an “outperform” rating and a $49.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $48.00 price target on shares of Progyny in a research report on Wednesday, February 28th. Truist Financial restated a “buy” rating and issued a $46.00 price objective on shares of Progyny in a report on Wednesday, April 17th. Leerink Partnrs reaffirmed an “outperform” rating on shares of Progyny in a report on Monday, February 26th. Finally, KeyCorp lowered their price target on shares of Progyny from $45.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 28th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $48.30.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.